Courtesy of Celgene Corporation
  • Previous Rank
    305
  • Revenues ($M)
    11229
  • Revenue Percent Change
    21.3
  • Profits ($M)
    1999.2
  • Profits Percent Change
    24.8
  • Assets ($M)
    28086
  • Employees
    7132
  • Market Value — as of March 31, 2017 ($M)
    96802

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Company Info

CEOMark J. Alles
CEO TitleChief Executive Officer & Director
SectorHealth Care
IndustryPharmaceuticals
HQ LocationSummit, NJ
Websitewww.celgene.com
Years on Fortune 500 List6
Employees7,132

Key Financials (Last Fiscal Year)

Revenues ($M)$11,229
Profits ($M)$1,999.2
Assets ($M)$28,086
Total Stockholder Equity ($M)$6,599
Market Value — as of March 31, 2017 ($M)$96,802

Profit Ratios

Profit as % of Revenues17.8%
Profits as % of Assets7.1%
Profits as % of Stockholder Equity30.3%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)2
EPS % Change (from 2015)28.4%
EPS % Change (5 year annual rate)11.8%
EPS % Change (10 year annual rate)39.4%

Total Return

Total Return to Investors (2016)-3.3%
Total Return to Investors (5 year, annualized)27.9%
Total Return to Investors (10 year, annualized)14.9%